Current Report Filing (8-k)
April 02 2014 - 6:03AM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM 8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of
the Securities Exchange Act of 1934
April 2, 2014
Date
of Report (Date of earliest event reported)
AGENUS INC.
(Exact
name of registrant as specified in its charter)
DELAWARE
|
000-29089
|
06-1562417
|
(State or other jurisdiction
of incorporation)
|
(Commission
File Number)
|
(IRS Employer
Identification No.)
|
3 Forbes Road
Lexington, MA
|
02421
|
(Address
of principal executive offices)
|
(Zip
Code)
|
781-674-4400
(Registrant’s
telephone number, including area code)
Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any
of the following provisions (see General Instruction A.2. below):
⃞
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR
230.425)
⃞
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
⃞
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
240.14d-2(b))
⃞
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
240.13e-4(c))
Item 8.01 Other Events
Agenus Inc. today announced that GlaxoSmithKline’s (“GSK”) MAGRITi
study, a Phase 3 randomized, blinded, placebo-controlled MAGE-A3ii
cancer immunotherapeutic trial in non-small cell lung cancer (NSCLC)
patients, which contains Agenus’QS-21 Stimulon®
adjuvant, will be stopped. GSK announced that it will not be possible
to identify a sub-population of gene-signature positive NSCLC patients
that may benefit from the treatment.
i A double-blind, randomised, placebo-controlled Phase III trial to
assess the efficacy of recMAGE-A3 + AS15 antigen-specific cancer
immunotherapeutic as adjuvant therapy in patients with MAGE-A3 positive
NSCLC (MAGRIT, NCT00480025).
ii MAGE-A3 cancer immunotherapeutic consists of recombinant MAGE-A3
protein and a novel immunostimulant AS15 (a combination of QS-21 Stimulon®
adjuvant, monophosphoryl lipid A, and CpG7909, a TLR-9 agonist, in a
liposomal formulation).
Item 9.01 Financial Statements and Exhibits
(d) Exhibits
The following exhibit is filed herewith:
99.1 Press
Release dated April 2, 2014
SIGNATURES
Pursuant to
the requirements of the Securities Exchange Act of 1934, the Registrant
has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
|
AGENUS INC.
|
|
|
Date: April 2, 2014
|
By:
|
/s/ Garo H. Armen
|
|
|
|
Garo H. Armen
|
|
Chief Executive Officer
|
EXHIBIT INDEX
Exhibit No.
|
|
Description of Exhibit
|
|
|
|
99.1
|
|
Press Release dated April 2, 2014
|
Agenus (NASDAQ:AGEN)
Historical Stock Chart
From Jun 2024 to Jul 2024
Agenus (NASDAQ:AGEN)
Historical Stock Chart
From Jul 2023 to Jul 2024